New York headquartered Pfizer Inc.'s shares saw a drop of 1.41%, finishing Tuesday's trading session at $32.06. A total volume of 32.10 million shares was traded, which was above their three months average volume of 26.81 million shares. The stock is trading below its 50-day moving average by 0.06%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 39.78.
On January 05th, 2017, ICU Medical, Inc. announced that ICU Medical and Pfizer have modified the terms of the definitive agreement entered into on October 06th, 2016, under which ICU Medical will acquire the Hospira Infusion Systems (HIS) business from Pfizer. These modifications are a result of recent changes in performance of HIS that affect previously announced expectations for the transaction. Under the terms of the modified agreement, the aggregate purchase price will be adjusted to be no more than $900 million (versus $1 billion as originally agreed). See our free and comprehensive research report on PFE at:
On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 10.59 million shares, and ended the session 1.38% lower at $61.48. The stock has gained 4.43% since the start of this year. The Company's shares are trading 1.02% and 4.62% above their 50-day and 200-day moving averages, respectively. Furthermore, shares of Merck & Co., which provides healthcare solutions worldwide, have an RSI of 53.12.
On January 10th, 2017, Merck announced that the US FDA has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the Company's anti-PD-1 therapy, plus chemotherapy for the first-line treatment of patients with metastatic or advanced non-squamous non-small cell lung cancer regardless of PD-L1 expression and with no EGFR or ALK genomic tumor aberrations. This is the first application for regulatory approval of KEYTRUDA in combination with another treatment. The FDA granted Priority Review with a PDUFA, or target action, date of May 10th, 2017. The sBLA will be reviewed under the FDA's Accelerated Approval program.
On January 13th, 2017, research firm Bryan Garnier initiated a 'Buy' rating on the Company's stock. MRK free research report PDF is just a click away at:
Shares in North Chicago, Illinois-based AbbVie Inc. closed at $61.86, slightly down 0.21% from the last trading session. The stock recorded a trading volume of 8.44 million shares, which was higher than its three months average volume of 8.10 million shares. The Company's shares have gained 1.32% in the last one month and 3.85% over the previous three months. The stock is trading 1.80% above its 50-day moving average and 1.30% above its 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 49.01.
On January 09th, 2017, AbbVie, life-sciences startup Genomics Medicine Ireland Limited, and WuXi NextCODE, the global contract genomics organization, announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide. Financial terms were not disclosed. Sign up for your complimentary report on ABBV at:
Johnson & Johnson
At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson & Johnson ended 0.24% higher at $114.87 with a total trading volume of 6.26 million shares. The stock is trading above its 50-day moving average by 0.04%. Shares of the Company, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 46.33.
On January 03rd, 2017, Johnson & Johnson announced that its Board of Directors has declared a cash dividend for Q1 2017 of $0.80 per share on its common stock. The dividend is payable on March 14th, 2017 to shareholders of record at the close of business on February 28th, 2017. Register for free on Stock-Callers.com and download the latest research report on JNJ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA